New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
16:07 EDTCTICCell Therapeutics sees FY13 loss from operations $60M-$65M
For 2013, loss from operations is expected to be approximately $60M-$65M, excluding non-cash stock-based compensation expense. The projected decrease in 2013 loss from operations, compared to 2012, primarily relates to expected changes in contribution margin from PIXUVRI commercial operations, as it intends to operate the commercial business with a net positive contribution; SG&A expenses, including sales and marketing expenses to drive sales of PIXUVRI; and R&D expenses.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
16:54 EDTCTICCTI BioPharma files to sell 9M shares of common stock for holders
16:40 EDTCTICCTI BioPharma files $200M mixed securities shelf
Subscribe for More Information
November 19, 2014
07:09 EDTCTICJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 17, 2014
11:06 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 13, 2014
13:32 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use